Current and emerging ALS biomarkers: utility and potential in clinical trials
- 8 October 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 18 (11) , 871-886
Abstract
Introduction: Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder which results in progressive muscle weakness as a prominent feature. However, clinical and pathogenic heterogeneity with regard to anatomical sites of disease onset and progression overtime are important features of the disease which have frustrated attempts to inform patients about their prognosis as well as limited the potential successes of therapeutic studies. Areas covered: This article discusses: clinical biomarkers which can be measured by history, physical examination, and clinical scales of disability; genetic markers of ALS that may help to distinguish various ALS subtypes; fluid-based biomarkers are actively being pursued for their utility in understanding disease progression and prognosis; electrophysiological studies that are now widely used in ALS clinical trials; neuroimaging biomarkers whose development has been accelerated with evolving techniques. Expert commentary: The investigation and development of biomarkers that could aid in diagnosis of ALS at earlier time points, prognostic biomarkers that could inform about the natural history of these heterogeneous presentations, predictive biomarkers aiding in understanding a potential response to therapy, and pharmacodynamic biomarkers to assess target engagement arguably represent the most important goals for improving ALS care and advancing ALS therapeutics.Keywords
This publication has 159 references indexed in Scilit:
- Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survivalEMBO Molecular Medicine, 2012
- Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansionActa Neuropathologica, 2012
- A proposed staging system for amyotrophic lateral sclerosisBrain, 2012
- Electrical impedance myography for monitoring motor neuron loss in the SOD1 G93A amyotrophic lateral sclerosis ratClinical Neurophysiology, 2011
- TAR DNA-binding protein 43 in neurodegenerative diseaseNature Reviews Neurology, 2010
- The relationship between uric acid levels and Huntington's disease progressionMovement Disorders, 2010
- Urate as a Predictor of the Rate of Clinical Decline in Parkinson DiseaseArchives of Neurology, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALSProceedings of the National Academy of Sciences, 2008
- TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral SclerosisArchives of Neurology, 2008